Swedbank AB Sells 151,995 Shares of Boston Scientific Co. (NYSE:BSX)

Swedbank AB decreased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 10.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,278,930 shares of the medical equipment provider's stock after selling 151,995 shares during the period. Swedbank AB owned about 0.09% of Boston Scientific worth $114,234,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BSX. State Street Corp grew its holdings in shares of Boston Scientific by 2.3% during the third quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock valued at $5,266,522,000 after buying an additional 1,389,172 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Boston Scientific by 2.2% in the third quarter. Wellington Management Group LLP now owns 32,820,828 shares of the medical equipment provider's stock worth $2,750,385,000 after purchasing an additional 718,515 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Boston Scientific by 1.7% during the third quarter. Geode Capital Management LLC now owns 29,584,841 shares of the medical equipment provider's stock worth $2,469,607,000 after purchasing an additional 480,729 shares during the period. Charles Schwab Investment Management Inc. grew its position in Boston Scientific by 0.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 8,018,377 shares of the medical equipment provider's stock valued at $671,940,000 after purchasing an additional 64,720 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its position in Boston Scientific by 17.5% in the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider's stock worth $457,138,000 after buying an additional 815,403 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded up $0.26 during midday trading on Thursday, reaching $102.97. 6,343,500 shares of the company's stock traded hands, compared to its average volume of 5,877,720. Boston Scientific Co. has a one year low of $62.63 and a one year high of $104.25. The stock has a 50 day moving average of $92.99 and a 200 day moving average of $85.93. The company has a market cap of $151.75 billion, a price-to-earnings ratio of 85.10, a P/E/G ratio of 2.63 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48.

Wall Street Analyst Weigh In

Several research firms have commented on BSX. TD Cowen boosted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, December 12th. Royal Bank of Canada boosted their price objective on Boston Scientific from $95.00 to $98.00 and gave the company an "outperform" rating in a research report on Thursday, October 24th. StockNews.com upgraded Boston Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday. Needham & Company LLC reiterated a "hold" rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Finally, Citigroup lifted their target price on Boston Scientific from $98.00 to $107.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $97.26.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares of the company's stock, valued at $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the transaction, the director now owns 39,398 shares in the company, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,989 shares of company stock worth $2,702,261. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.